Keywords: imclone, erbitux, shows, increased, survival, head, neck

Imclone's Erbitux shows increased survival in head and neck cancer

Article | 30 May 2005

Print This

Further data on the use of US group Imclone System's Erbitux (cetuximab) in recurrent and metastatic squamous cell carcinoma of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in